AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Medina S, Tokuyama N, Putcha V, Pathak T, Fu P, Thomas H, Subhash VV, Yip S, Lin HM, Horvath LG, Kench JG, Zhang A, Stockler MR, Joshua AM, Azad A, Oakes SR, Davis ID, Sweeney CJ, Madabhushi A

Open source

DOI: 10.1158/1078-0432.ccr-26-0871
Published: 2026 Jun 26
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0871,
  title = {AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.},
  author = {Medina S and Tokuyama N and Putcha V and Pathak T and Fu P and Thomas H and Subhash VV and Yip S and Lin HM and Horvath LG and Kench JG and Zhang A and Stockler MR and Joshua AM and Azad A and Oakes SR and Davis ID and Sweeney CJ and Madabhushi A},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-0871},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0871}
}

RIS

TY  - JOUR
TI  - AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
AU  - Medina S
AU  - Tokuyama N
AU  - Putcha V
AU  - Pathak T
AU  - Fu P
AU  - Thomas H
AU  - Subhash VV
AU  - Yip S
AU  - Lin HM
AU  - Horvath LG
AU  - Kench JG
AU  - Zhang A
AU  - Stockler MR
AU  - Joshua AM
AU  - Azad A
AU  - Oakes SR
AU  - Davis ID
AU  - Sweeney CJ
AU  - Madabhushi A
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-0871
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0871
ER  -

APA

S, M., N, T., V, P., T, P., P, F., H, T., VV, S., S, Y., HM, L., LG, H., JG, K., A, Z., MR, S., AM, J., A, A., SR, O., ID, D., CJ, S., & A, M. (2026). AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0871

Source records

pubmed · retrieved 2026-09-26T05:16:51.185Z
europe-pmc · retrieved 2026-09-26T05:16:51.203Z